Trinity Biotech Plc ADR(TRIB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -52.93 | Insider Own | 3.57% | Shs Outstand | 0.6M | Perf Week | 6.72% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | -24.02% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | - | Inst Own | 5.14% | Short Float | 1.29% | Perf Quarter | -39.06% |
| Income | -0.03B | P/S | 0.1 | EPS this Y | - | Inst Trans | -0.66% | Short Ratio | 0.38 | Perf Half Y | -60.63% |
| Sales | 0.05B | P/B | - | EPS next 5Y | - | ROA | -35.91% | Short Interest | 0.01M | Perf YTD | -69.87% |
| Book/sh | -111.67 | P/C | 0.89 | EPS past 3/5Y | 30.77% -5.58% | ROE | - | 52W High | -86.38% ($52.50) | Perf Year | -78.33% |
| Cash/sh | 8.03 | P/FCF | - | Sales past 3/5Y | -11.12% -15.62% | ROIC | - | 52W Low | 42.71% ($5.01) | Perf 3Y | -91.26% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.65% | Gross Margin | 32.95% | Volatility(W/M) | 18.39% 10.79% | Perf 5Y | -97.63% |
| Dividend TTM | - | EV/Sales | 2.92 | Sales Y/Y TTM | -13.28% | Oper. Margin | -23.88% | ATR (14) | 0.86 | Perf 10Y | -99.27% |
| Dividend Ex-Date | 2015/6/5 | Quick Ratio | 0.12 | EPS Q/Q | 52.53% | Profit Margin | -70.1% | RSI (14) | 44.36 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.25 | Sales Q/Q | 43.08% | SMA20 | 2.07% ($7) | Beta | 1 | Target Price | $450 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -24.08% ($9.42) | Rel Volume | 1.96 | Prev Close | $5.77 |
| Employees | 287 | LT Debt/Eq | - | EPS/Sales Surpr. | -311.83% -3.9% | SMA200 | -58.05% ($17.04) | Avg Volume(3M) | 0.02M | Price | $7.15 |
| IPO | 1992/10/21 | Option/Short | No/Yes | Trades | 281 | Volume | 41,635 | Change | 23.92% |
🧪 Headquartered in Dublin, Ireland, this company provides human diagnostics and diabetes management solutions. It supplies diagnostic reagents and devices for HIV, hepatitis, and diabetes (HbA1c) to public and private healthcare institutions worldwide, while also developing a next-generation non-invasive (no skin penetration) continuous glucose monitor (CGM+), making it a hybrid diagnostics and diabetes device company.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded more than usual That is 196% of its average volume.
TRIB has weak earnings and a weak balance sheet
Of every $100 in sales, $23.88 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $10. Peers typically go for $155.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.6%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.1%.
Tap to view numbers
It ranks #131 of 143 in the industry
Based on market cap of $5M.
VVOS#129 Vivos Therapeutics Inc $5M PER - 
POAS#130 Phaos Technology (Cayman) Holdings Ltd $5M PER - TRIB#131 Trinity Biotech Plc ADR $5M PER - 
AIDX#132 20/20 Biolabs Inc $5M PER - 
ICCM#133 Icecure Medical Ltd $4M PER - 
FAQ
What kind of company is TRIB?
TRIB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TRIB?
The market cap of TRIB is approximately $5M, ranking 5,689 within its sector.
What is the 52-week high and low for TRIB?
TRIB has recorded a 52-week high of $52.50 and a low of $5.01.
